论文部分内容阅读
目的探讨桂哌齐特联合黄芪注射液治疗充血性心力衰竭患者的临床效果。方法将150例充血性心力衰竭患者随机分为两组。治疗组在常规组强心、利尿和扩血管的基础上加用桂哌齐特联合黄芪注射液。治疗前后作肌酸磷酸激酶同工酶、血浆肌钙蛋白I测定。彩色超声心动图测定心功能。结果治疗组治疗后CK-MB、cTnI和ESV均低于常规组,而EF与临床疗效高于常规组,差异有统计学意义(P<0.05)。结论桂哌齐特联合黄芪注射液能降低充血性心力衰竭患者血清中CK-MB和cTnI浓度,改善心功能,提高充血性心力衰竭治疗效果,值得临床推广。
Objective To investigate the clinical effect of cinepazide and astragalus injection in patients with congestive heart failure. Methods 150 patients with congestive heart failure were randomly divided into two groups. The treatment group in the conventional group of cardiac, diuretic and vasodilator plus plus cinepazide combined Astragalus injection. Before and after treatment for creatine phosphokinase isoenzyme, plasma troponin I determination. Color Echocardiography for the determination of cardiac function. Results After treatment, the CK-MB, cTnI and ESV of the treatment group were lower than those of the conventional group, while the clinical efficacy of EF was higher than that of the conventional group. The difference was statistically significant (P <0.05). Conclusion Cinepazide combined with Astragalus injection can reduce the concentrations of CK-MB and cTnI in serum of patients with congestive heart failure, improve cardiac function and improve the therapeutic effect of congestive heart failure, which is worthy of clinical promotion.